IVD MEDICAL(01931) reached a significant strategic cooperation with Renhe International to jointly build the world's first vertical RWA exchange focusing on the OTC field.

IVD MEDICAL (01931) announced that the group has reached a strategic cooperation with Renhe Pharmacy Co., Ltd. (000650.SZ), its indirect wholly-owned subsidiary Renhe International, to jointly establish the world's first vertical RWA exchange dedicated to over-the-counter (OTC) drugs in the United States. This cooperation is a key milestone and benchmark case in the successful implementation of the group's "ETHK on-chain financial ecosystem strategy" and the "Global RWA ExchangeSO Exchange" business model, aiming to create a replicable template to verify the feasibility and huge potential of this innovative model. The strategic cooperation with Renhe Pharmacy marks a new stage in the group's "ETHK" on-chain financial ecosystem strategy, demonstrating the value realization of their innovation in the "ETHK Global RWA ExchangeSO Exchange" business model on a global stage for the first time. This move deeply reflects the group's excellent planning and execution capabilities in "focusing on core strategies, achieving scalable replication, and building differentiated advantages," showcasing their determination to build a truly open, empowering, and mutually beneficial new digital financial ecosystem through cutting-edge innovation technology and rigorous compliance practices. IVD MEDICAL firmly believes that the ultimate mission of financial technology is to serve the real economy and create inclusive value. This collaboration is a vivid interpretation of this belief. The group aims to empower classic national brands like Renhe Pharmacy with technology to achieve digital transformation and expand their successful ecosystem model to various industries, ultimately serving the grand narrative of national industrial upgrading and digital economic development, and fulfilling the company's corporate original intention and ultimate vision of "benefiting the country, the people, and the world." The company looks forward to the global first OTC RWA exchange not only becoming a platform for value circulation but also a super connector between global innovative health resources and the vast Chinese market demand, contributing to the improvement of human health and well-being. The Board of Directors firmly believes that this strong alliance will create tremendous synergies, not only generating profound and positive momentum for the strategic transformation and value reassessment of both companies but also injecting strong momentum for the group's sustainable business growth and financial performance in the future. The group will work closely with Renhe Pharmacy, pooling the strengths of both parties to ensure the successful establishment and stable operation of the world's first OTC RWA exchange with high standards and quality, working together to create a better future.